

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol* 2017; published online May 16. [http://dx.doi.org/10.1016/S1470-2045\(17\)30312-1](http://dx.doi.org/10.1016/S1470-2045(17)30312-1).

Supplementary appendix

Supplement to: Diéras V, Miles D, Verma S, et al. Final overall survival results from the phase 3 EMILIA study of trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer.

Table S1: Study investigators

Investigator	Site	Number of patients recruited
Do-Youn Oh	Seoul National University Hospital, Korea	33
Jungsil Ro	National Cancer Center, Korea	27
Sunil Verma	Sunnybrook Odette Cancer Centre, Canada	24
Constanta Timcheva	SHATO, Sofia, Bulgaria	23
Joo-Hyuk Sohn	Yonsei University College of Medicine, Korea	21
Tadeusz Pienkowski	Centrum Onkologii, Marii Skłodowskiej-Curie Clinic, Poland	19
Young-Hyuck Im	Samsung Medical Centre, Korea	17
Gilles Romieu	Centre Val d'Aurelle Paul Lamarque-Hopital de Jour et de Sema, France	17
Shailendra Verma	The Ottawa Hospital, Canada	14
Jonathan Polikoff	Kaiser Permanente, San Diego, California, USA	12
Anne Armstrong	Christie Hospital, France	12
Jens Huober	Kantonsspital St. Gallen, Brustzentrum, Switzerland	12
Lowell Hart	Florida Cancer Specialists & Research Institute, Fort Myers, Florida, USA	11
Mario Campone	Ico Rene Gauducheau, France	11
Raymond Ng	National Cancer Centre, Taiwan	11
Soo Chin Lee	National University Hospital, Singapore	11
Vladmir Semiglazov	Petrov Research Institute of Oncology, Russia	11
Laurent Gressot	Northwest Cancer Center, Houston, Texas, USA	10
Louis Fehrenbacher	Kaiser Permanente, Roseville, California, USA Kaiser Permanente, Walnut Creek, California, USA Kaiser Permanente, Santa Clara, California, USA Kaiser Permanente, Vallejo, California, USA	10

	Kaiser Permanente, San Jose, California, USA	
Mark Verrill	Freeman Hospital, Northern Centre for Cancer Care, United Kingdom	10
Veronique Dieras	Institut Curie, France	10
Kay Friedrichs	Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Germany	10
Mei-Ching Liu	Koo Foundation Sun Vat-Sen Cancer Center, Taiwan	10
Noemia Afonso	Instituto Portugues de Oncologia, Portugal	10
Sara Hurvitz	UCLA Oncology, Los Angeles, California, USA	9
Timothy Pluard	Siteman Cancer Center, St Louis, Missouri, USA	9
Giuliano Borges	Clinica de Neoplasias Litoral, Italy	9
Jose Luiz Pedrini	Hospital Nossa, Senhora da Conceição, Brazil	9
Rodrigo Araujo	Instituto Nacional do Cancer, Centro de Estudos, Brazil	9
Antonio Anton Torres	Hospital Miguel Servet, Spain	9
Hsien-Kun Chang	Chang Gung Memorial Hospital, Taiwan	9
David Riseberg	Mercy Medical Center, Baltimore, Maryland, USA	8
Shankar Sundaram	Sharp Healthcare, San Diego, California, USA	8
David Miles	Mount Vernon Hospital Centre for Cancer Treatment, France	8
Roberto Hegg	Hospital Perola Bygton, Centro da Referencia da Saude da Mulher, Brazil	8
Elzbieta Staroslawska	Centrum Onkologii, Ziemi Lubelskiej, Poland	8
Renata Szoszkiewicz	Wielkopolskie Centrum Onkologii, Oddzial Chemioterapii, Poland	8
Gerd Graffunder	Frauenarzt-Zentrum Zehlendorf, Germany	8
Manuel Ruiz Borrego	Hospital Virgen del Rocio, Spain	8
Kimberly Blackwell	Duke University Medical Center, Durham, North Carolina, USA	7
Jacek Jassem	Uniwersyteckie Centrum Kliniczne, Poland	7
Patricia Gomez Pardo	University Hospital Vall d'Hebron, Spain	7
Antoaneta Tomova	District Oncology Dispensary, Bulgaria	7
Leif Klint	Sahlgrenska Universitetssjukhuset, Sweden	7
Simona Borstnar	Institute of Oncology Ljubljana, Slovenia	7
Denise Yardley	Sarah Cannon Research Institute, Nashville, Tennessee, USA	6
Sandra Swain	Washington Cancer Institute, Washington, DC, USA	6
Karen Gelmon	BC Cancer Research Centre, Canada	6

Susan Ellard	Centre of the Southern Interior, Canada	6
Wilson Miller	Jewish General Hospital, Canada	6
Peter Barrett-Lee	Velindre Cancer Centre, United Kingdom	6
Thierry Delozier	Centre Francois Baclesse, Comite Sein, France	6
Fausto Roila	Azienda Ospedaliera S. Maria, Italy	6
Francesco Cognetti	Istituto Regina Elena, Italy	6
Jefferson Vinholes	CliniOnco Centro de Novos Tratamentos, Brazil	6
Jeffrey Yachnin	Malarsjukhuset, Sweden	6
Semir Beslija	Clinic of Oncology, Bosnia and Herzegovina	6
Adam Brufsky	Magee-Women's Hospital, Pittsburgh, Pennsylvania, USA	5
George Somlo	City of Hope National Medical Center, Duarte, California, USA	5
James Knost	Illinois Cancer Care, Peoria, Illinois, USA	5
Mansoor Saleh	Georgia Cancer Specialists, Atlanta, Georgia, USA	5
Melody Cobleigh	Rush University Medical Center, Chicago, Illinois, USA	5
Teresa Helsten	UC San Diego Moores Cancer Center, San Diego, California, USA	5
Thomas Budd	Cleveland Clinic Foundation, Cleveland, Ohio, USA	5
Timothy Moore	The Zangmeister Center, Ohio Cancer Center, Columbus, Ohio, USA	5
Catherine Prady	Hôpital Charles Lemoyne, Canada	5
Tallal Hussein Younis	Capital Health, Canada	5
Marc Debled	Institut Bergonie, Gastroenterologie & Oncologie, France	5
Nicholas Turner	Royal Marsden Hospital, United Kingdom	5
Andrea Martoni	Policlinco Sant'Orsola-Malpighi, Italy	5
Luca Gianni	Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy	5
Carsten Hielscher	gSUND Gynäkologie Kompetenzzentrum Stralsund, Germany	5
Michael Untch	Helios Klinikum Berlin-Buch Klinik für Gynäkologie und Geburtshilfe Brustzentrum, Germany	5
Andres Redondo Sanchez	Hospital de la Paz Madrid, Spain	5
Assen Dudov	Oncology Center, Sofia, Bulgaria	5
Gabriel Tellez-Trevilla	Centro Oncológico Estatal, Mexico	5
Minna Tanner	Tampere University Hospital, Finland	5
Alejandra Perez	Memorial Cancer Institute, Hollywood, Florida, USA	4

Daniel Budman	North Shore-Long Island Jewish Health, Great Neck, New York, USA	4
Ian E. Krop	Dana-Farber Cancer Institute, Boston, Massachusetts, USA Massachusetts General Hospital, Boston, Massachusetts, USA	4
James Waisman	Breastlink Medical Group, Murrieta, California, USA	4
Mikhail Shtivelband	Ironwood Cancer Treatment and Research, Chandler, Arizona, USA	4
Robert Hermann	Northwest Georgia Oncology Centers, Marietta, Georgia, USA	4
Ruth M. O'Regan	Emory University, Druid Hills, Georgia, USA	4
Thomas Cosgriff	Hematology and Oncology Specialists, Metairie, Louisiana, USA	4
Troy Guthrie, Jr.	Baptist Cancer Institute, Jacksonville, Florida, USA	4
Mark Beresford	Bristol Oncology Centre, United Kingdom	4
Paul Ellis	St. Thomas Hospital, United Kingdom	4
Tamas Hickish	Royal Bournemouth General Hospital, United Kingdom Poole General Hospital, United Kingdom	4
Corrado Boni	Arcispedale Santa Maria Nuova, Servizio di Oncologia, Italy	4
Diana Crivellari	Centro di Riferimento Oncologico, Italy	4
Dino Amadori	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy	4
Giuseppe Curigliano	Istituto Europeo di Oncologia, Italy	4
Helio Pinczowski	Centro de Oncologia e Hematologia da Faculdade de Medicina, Italy	4
Manfred Welslau	Studienzentrum, Germany	4
Peter Klare	Gemeinschaftspraxis Dres. Klare, Kittel, Müller, und Wetzlar, Germany	4
Kun-Ming Rau	Kaohsiung Chang Gung Memorial Hospital, Taiwan	4
Marcelino Gaytan-Angel	Centro de Investigacion, Clinica del Pacifico, Mexico	4
Tuomo Alanko	Docrates Clinic, Finland	4
Christopher Ruud	Scott & White Hospital, Temple, Texas, USA	3
David Berd	Eastern Regional Medical Center, Philadelphia, Pennsylvania, USA	3
David Henry	Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, USA	3
Grace Wang	Advanced Medical Specialties, Miami, Florida, USA	3
Jonathon Goldberg	Northern Westchester Hospital Cancer Treatment and Wellness Center, Mt. Kisco, New York, USA	3
Joseph Baar	University Hospitals of Cleveland, Cleveland, Ohio, USA	3

Marc L. Citron	ProHEALTH Care Associates, Lake Success, New York, USA	3
Ravi Patel	Comprehensive Blood & Cancer Center, Bakersfield, California, USA	3
Sanjiv Modi	Joliet Oncology Hematology Associates, Joliet, Illinois, USA	3
Shaker Dakhil	Cancer Center of Kansas, Wichita, Kansas, USA	3
Steven Limentani	Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, USA	3
Theodore Walters	St. Luke's Mountain States Tumor Institute, Boise, Idaho, USA St. Luke's Mountain States Tumor Institute, Twin Falls, Idaho, USA St. Luke's Mountain States Tumor Institute, Meridian, Idaho, USA	3
Seock Ah Im	Seoul National University Hospital, Korea	3
Frank Priou	Les Oudairies-Hematologie & Oncologie, France	3
Helene Simon	Hôpital Morvan, France	3
Antonio Contu	Ospedale Civile, Italy	3
Ruffo Freitas Júnior	Hospital Araujo Jorge, Brazil	3
Sabino De Placido	Universita Fredrico II, Italy	3
Jerzy Zaluski	Wielkopolskie Centrum Onkologii, Poland	3
Georg Heinrich	Schwerpunktpraxis, Germany	3
Holger Eidtmann	Universitätsklinikum Schleswig-Holstein, Germany	3
Antonio Llombart	Hospital Arnau de Vilanova, Spain	3
Serafin Morales Murillo	Hospital Arnau de Vilanova, Spain	3
Violina Taskova	MHAT Sveta Anna, Bulgaria	3
Hwei-Chung Wang	China Medical University Hospital, Taiwan	3
Janice Tsang	Queen Mary Hospital, Hong Kong	3
Anisa Hassan	Freeman Cancer Institute, Joplin, Missouri, USA	2
Brian Dicarlo	Central Coast Medical Oncology, Santa Maria, California, USA	2
Elaina Gartner	Wayne State University, Detroit, Michigan, USA	2
Francis Senecal	Northwest Medical Specialties, Tacoma, Washington, USA	2
Ines Sanchez	Texas Oncology, El Paso, Texas, USA	2
Ira Oliff	Orchard Research, New York, NY, USA	2
John Charlson	Medical College of Wisconsin, Milwaukee, Wisconsin, USA	2
Luis Meza	Cancer Center of Acadiana at Lafayette, Lafayette, Louisiana, USA	2

Pearl Seo	University of Miami Health System, Miami, Florida, USA	2
Richard Frank	Norwalk Hospital, Norwalk, Connecticut, USA	2
Richard Orłowski	Carolina Oncology Specialists, PA, Durham, North Carolina, USA	2
Richy Agajanian	The Oncology Institute of Hope and Innovation, Downey, California, USA	2
Rita Blanchard	Boston Medical Center, Boston, Massachusetts, USA	2
Robert Somer	Anderson Cancer Center at Cooper, Camden, New Jersey, USA	2
Rupesh Parikh	Comprehensive Cancer Centers of Nevada, Henderson, Nevada, USA	2
Shobha Chitneni	Hematology-Oncology Associates, Bettendorf, Iowa, USA	2
Stanley Waintraub	John Theurer Cancer Center, Hackensack, New Jersey, USA	2
Steven Papish	Morristown Memorial Hospital, Morristown, New Jersey, USA	2
Steven Roshon,	North Coast Cancer Center-Cleveland Clinic, Cleveland, Ohio, USA	2
Soo Hyeon Lee	Yonsei University College of Medicine, Korea	2
Andre Robidoux	Hôtel Dieu de Montréal, Canada	2
Andrew Scarfe	Cross Cancer Institute, Canada	2
Marc Webster	Tom Baker Cancer Centre, Canada	2
Ann-Claire Hardy-Bessard	Clinique Armoricaine de Radiologie, France	2
Djelila Allouache	Centre Francois Baclesse, Comite Sein, France	2
Elisabeth Luporsi	Centre Alexis Vautrin, Recherche Clinique, France	2
Julien Grenier	Clinique Sainte Catherine, Hôpital de Semaine, France	2
Alfredo Falcone	Ospedale Santa Chiara, Italy	2
Rodrigo Pereira	Irmandade Santa Casa de Misericórdia de Porto Alegre, Brazil	2
Vera Lucia Silva Teixeira	Oncoclinica, Brazil	2
Kazimierz Drosik	Opolskie Centrum Onkologii, Oddzial Onkologii Klinicznej, Poland	2
Marek Wojtukiewicz	Bialostockie Centrum Onkologii, Oddzial Onkologii Klinicznej, Poland	2
Elmar Stickeler	Uniklinik Freiburg, Frauenklinik, Germany	2
Eva Ciruelos Gil	University Hospital 12 de Octubre, Spain	2
Dah-Cherng Yeh	Taichung Veterans General Hospital, Taiwan	2
Ralph Winterhalder	Luzerner Kantonsspital, Switzerland	2
Carlos Alberto Hernandez	Oaxaca Site Management Organization, Mexico	2

Zdenka Gojkovic	Clinical Center Banja Luka, Bosnia and Herzegovina	2
Paul Francis Pua	Veterans Memorial Medical Centre, Philippines	2
Anca Bulgaru	Eastern Connecticut Hematology, Norwich, Connecticut, USA	1
Andrzej Kudelka	Stony Brook University Cancer Center, Stony Brook, New York, USA	1
Ashwin Kashyap	Tri-Valley Oncology-Hematology Association, Thousand Oaks, California, USA	1
Barbara Bower	Southdale Cancer Clinic, Edina, Minnesota, USA	1
Beth Hellerstedt	Texas Oncology-Austin Central, Austin, Texas, USA	1
David Chan	Cancer Center Oncology Medical Group, La Mesa, California, USA	1
Diana Medgyesy	Front Range Cancer Specialist, Fort Collins, Colorado, USA	1
Haluk Tezcan	Kootenai Cancer Center, Post Falls, Indiana	1
Haythem Ali	Henry Ford Hospital, Detroit, Michigan, USA	1
James Neidhart	San Juan Oncology, Farmington, New Mexico, USA	1
James Wade	Cancer Care Specialists of Illinois, Swansea, Illinois, USA	1
John M. Wallmark	Associates in Oncology and Hematology, Bethesda, Maryland, USA	1
Jonathan Eneman	York Hospital, York, Maine, USA	1
Joseph Leach	Park Nicollet Institute, St. Louis Park, Minnesota, USA	1
K. M. Steve Lo	Hematology Oncology PC, Stamford, Connecticut, USA	1
Mary Wilkinson	Medical Oncology & Hematology, Fairfax, Virginia, USA	1
Mehdi Moezi	Integrated Community Oncology Network, Jacksonville, Florida, USA	1
Neal Christiansen	Medical University of South Carolina, Charleston, South Carolina, USA	1
Nicholas Iannotti	Hematology Oncology Associates of the Treasure Coast, Stuart, Florida, USA	1
Paulette Blanchet	Cancer Center of Acadiana at Lafayette, Lafayette, Louisiana, USA	1
Ralph Boccia	Center for Cancer and Blood Disorders, Bethesda, Maryland, USA	1
Sudhathi Chennuru	Hematology Oncology Consultants, Westerville, Ohio	1
Sujatha Murali	Emory University, Druid Hills, Georgia, USA	1
William Conkright	Purchase Cancer Group, Paducah, Kentucky, USA	1
Andrew Robinson	Sudbury General Hospital, Canada	1
Amit Chakrabarti	Poole General Hospital, France	1
Bruno Coudert	Centre Georges Francois Leclerc, France	1

Eliot Sims	Queens Hospital-Romford Cardio Research	1
Jill Bishop	North Wales Cancer Treatment Centre, Glan Clwyd Hospital, United Kingdom	1
Armando Santoro	Istituto Clinico Humanitas, Italy	1
Claudia Bighin	Istituto Nazionale per la Ricerca sul Cancro, Italy	1
Filippo Montemurro	Istituto di Candiolo, Fondazione del Piemonte per L'Oncologia, Italy	1
Gilberto Amorim	Oncologistas Associados, Italy	1
Giulia Bianchi	Istituto Nazionale per lo Studio e la Cura dei Tumori, Italy	1
Lucia Del Mastro	Istituto Nazionale per la Ricerca sul Cancro, Italy	1
Marco Venturini	Ospedale Sacro Cuore don Calabria, Italy	1
Marcos Portella	Biocancer, Brazil	1
Oliver Tome	St. Vincentius-Kliniken Klinik für Frauenheilkunde Hebammenlehre, Germany	1
Volker Hagen	St. Johannes Hospital, Germany	1
Yon Dschin Ko	Betriebsstaette Johanniter-Krankenhaus, Germany	1
Jose Baselga	University Hospital Vall d'Hebron, Spain	1
Miguel Climent Duran	Istituto Valenciano de Oncologia, Spain	1
Johan Ahlgren	Gävle Sjukhus Onkologkliniken, Sweden	1
Olga Zharkova	State Institution of Healthcare Regional Clinical Oncology Dispensary, Russia	1
Maria Isabel Pazos	IPO de Coimbra, Portugal	1
Rikka Huovinen	Turku University Hospital, Finland	1
Soren Cold	Odense University Hospital, Denmark	1
Vinod Raina	Institute Rotary Cancer Hospital, AIIMS, India	1
Richard Isaacs	Palmerston North Hospital, Regional Cancer Treatment Service, New Zealand	1

Table S2: Summary of safety events

	Capecitabine plus lapatinib (n=488)				Trastuzumab emtansine (n=490)			
n (%)	Grade 1-2	Grade 3	Grade 4	Grade 5	Grade 1-2	Grade 3	Grade 4	Grade 5
Diarrhoea	286 (58.6%)	100 (20.5%)	3 (0.6%)	0 (0%)	115 (23.5%)	9 (1.8%)	0 (0%)	0 (0%)
Nausea	212 (43.4%)	12 (2.5%)	1 (0.2%)	0 (0%)	198 (40.4%)	4 (0.8%)	0 (0%)	0 (0%)
PPE syndrome	204 (41.8%)	86 (17.6%)	1 (0.2%)	0 (0%)	7 (1.4%)	0 (0%)	0 (0%)	0 (0%)
Fatigue	128 (26.2%)	16 (3.3%)	1 (0.2%)	0 (0%)	169 (34.5%)	11 (2.2%)	1 (0.2%)	0 (0%)
Rash	127 (26.0%)	7 (1.4%)	1 (0.2%)	0 (0%)	64 (13.1%)	0 (0%)	0 (0%)	0 (0%)
Vomiting	126 (25.8%)	23 (4.7%)	1 (0.2%)	0 (0%)	97 (19.8%)	5 (1.0%)	0 (0%)	0 (0%)
Decreased appetite	112 (23.0%)	5 (1.0%)	0 (0%)	0 (0%)	103 (21.0%)	2 (0.4%)	0 (0%)	0 (0%)
Mucosal inflammation	82 (16.8%)	9 (1.8%)	2 (0.4%)	0 (0%)	32 (6.5%)	1 (0.2%)	0 (0%)	0 (0%)
Asthenia	79 (16.2%)	8 (1.6%)	1 (0.2%)	0 (0%)	88 (18.0%)	4 (0.8%)	0 (0%)	0 (0%)
Headache	73 (15.0%)	4 (0.8%)	0 (0%)	0 (0%)	143 (29.2%)	4 (0.8%)	0 (0%)	0 (0%)
Stomatitis	69 (14.1%)	2 (0.4%)	0 (0%)	0 (0%)	20 (4.1%)	0 (0%)	0 (0%)	0 (0%)
Cough	67 (13.7%)	1 (0.2%)	0 (0%)	0 (0%)	99 (20.2%)	1 (0.2%)	0 (0%)	0 (0%)
Back pain	61 (12.5%)	2 (0.4%)	0 (0%)	0 (0%)	75 (15.3%)	4 (0.8%)	0 (0%)	0 (0%)
Constipation	60 (12.3%)	0 (0%)	0 (0%)	0 (0%)	137 (28.0%)	2 (0.4%)	0 (0%)	0 (0%)

Pain in extremity	57 (11.7%)	5 (1.0%)	0 (0%)	0 (0%)	69 (14.1%)	2 (0.4%)	0 (0%)	0 (0%)
Dyspepsia	55 (11.3%)	2 (0.4%)	0 (0%)	0 (0%)	51 (10.4%)	0 (0%)	0 (0%)	0 (0%)
Dry skin	54 (11.1%)	1 (0.2%)	0 (0%)	0 (0%)	17 (3.5%)	0 (0%)	0 (0%)	0 (0%)
Paronychia	53 (10.9%)	6 (1.2%)	0 (0%)	0 (0%)	2 (0.4%)	0 (0%)	0 (0%)	0 (0%)
Dizziness	52 (10.7%)	1 (0.2%)	0 (0%)	0 (0%)	61 (12.4%)	2 (0.4%)	0 (0%)	0 (0%)
Arthralgia	47 (9.6%)	0 (0%)	0 (0%)	0 (0%)	99 (20.2%)	3 (0.6%)	0 (0%)	0 (0%)
Pruritus	47 (9.6%)	0 (0%)	0 (0%)	0 (0%)	31 (6.3%)	1 (0.2%)	0 (0%)	0 (0%)
Increased AST	46 (9.4%)	7 (1.4%)	0 (0%)	0 (0%)	101 (20.6%)	22 (4.5%)	0 (0%)	0 (0%)
Abdominal pain	45 (9.2%)	7 (1.4%)	0 (0%)	0 (0%)	43 (8.8%)	3 (0.6%)	0 (0%)	0 (0%)
Insomnia	45 (9.2%)	1 (0.2%)	0 (0%)	0 (0%)	67 (13.7%)	3 (0.6%)	0 (0%)	0 (0%)
Nail disorder	45 (9.2%)	3 (0.6%)	0 (0%)	0 (0%)	18 (3.7%)	0 (0%)	0 (0%)	0 (0%)
Epistaxis	44 (9.0%)	0 (0%)	0 (0%)	0 (0%)	120 (24.5%)	2 (0.4%)	0 (0%)	0 (0%)
Upper abdominal pain	44 (9.0%)	1 (0.2%)	0 (0%)	0 (0%)	58 (11.8%)	2 (0.4%)	0 (0%)	0 (0%)
Pyrexia	43 (8.8%)	2 (0.4%)	0 (0%)	0 (0%)	99 (20.2%)	1 (0.2%)	0 (0%)	0 (0%)
Hyperbilirubinaemia	41 (8.4%)	6 (1.2%)	0 (0%)	0 (0%)	11 (2.2%)	2 (0.4%)	0 (0%)	0 (0%)
Nasopharyngitis	41 (8.4%)	0 (0%)	0 (0%)	0 (0%)	49 (10.0%)	0 (0%)	0 (0%)	0 (0%)
Upper respiratory tract infection	40 (8.2%)	0 (0%)	0 (0%)	0 (0%)	57 (11.6%)	0 (0%)	0 (0%)	0 (0%)

Dyspnoea	39 (8.0%)	1 (0.2%)	1 (0.2%)	0 (0%)	59 (12.0%)	4 (0.8%)	0 (0%)	0 (0%)
Increased ALT	39 (8.0%)	9 (1.8%)	0 (0%)	0 (0%)	78 (15.9%)	15 (3.1%)	0 (0%)	0 (0%)
Peripheral oedema	37 (7.6%)	1 (0.2%)	0 (0%)	0 (0%)	38 (7.8%)	0 (0%)	0 (0%)	0 (0%)
Decreased weight	35 (7.2%)	2 (0.4%)	0 (0%)	0 (0%)	36 (7.3%)	2 (0.4%)	0 (0%)	0 (0%)
Anaemia	30 (6.1%)	11 (2.3%)	0 (0%)	0 (0%)	49 (10.0%)	18 (3.7%)	1 (0.2%)	0 (0%)
Peripheral neuropathy	29 (5.9%)	1 (0.2%)	0 (0%)	0 (0%)	50 (10.2%)	9 (1.8%)	0 (0%)	0 (0%)
Depression	28 (5.7%)	1 (0.2%)	1 (0.2%)	0 (0%)	25 (5.1%)	1 (0.2%)	1 (0.2%)	0 (0%)
Increased blood bilirubin	28 (5.7%)	4 (0.8%)	0 (0%)	0 (0%)	18 (3.7%)	2 (0.4%)	0 (0%)	0 (0%)
Peripheral sensory neuropathy	27 (5.5%)	0 (0%)	0 (0%)	0 (0%)	30 (6.1%)	6 (1.2%)	0 (0%)	0 (0%)
Chest pain	26 (5.3%)	1 (0.2%)	0 (0%)	0 (0%)	39 (8.0%)	2 (0.4%)	0 (0%)	0 (0%)
Dry mouth	25 (5.1%)	1 (0.2%)	0 (0%)	0 (0%)	85 (17.3%)	0 (0%)	0 (0%)	0 (0%)
Erythema	24 (4.9%)	1 (0.2%)	0 (0%)	0 (0%)	15 (3.1%)	1 (0.2%)	0 (0%)	0 (0%)
Skin fissures	24 (4.9%)	3 (0.6%)	0 (0%)	0 (0%)	2 (0.4%)	0 (0%)	0 (0%)	0 (0%)
Hypokalaemia	23 (4.7%)	21 (4.3%)	1 (0.2%)	0 (0%)	37 (7.6%)	11 (2.2%)	0 (0%)	0 (0%)
Neutropenia	23 (4.7%)	16 (3.3%)	5 (1.0%)	0 (0%)	26 (5.3%)	9 (1.8%)	2 (0.4%)	0 (0%)
Musculoskeletal chest pain	21 (4.3%)	2 (0.4%)	0 (0%)	0 (0%)	18 (3.7%)	0 (0%)	1 (0.2%)	0 (0%)
Urinary tract infection	21 (4.3%)	0 (0%)	0 (0%)	0 (0%)	50 (10.2%)	3 (0.6%)	0 (0%)	0 (0%)

Dehydration	20 (4.1%)	7 (1.4%)	0 (0%)	0 (0%)	9 (1.8%)	0 (0%)	0 (0%)	0 (0%)
Dysgeusia	20 (4.1%)	1 (0.2%)	0 (0%)	0 (0%)	41 (8.4%)	0 (0%)	0 (0%)	0 (0%)
Increased blood alkaline phosphatase	20 (4.1%)	3 (0.6%)	0 (0%)	0 (0%)	23 (4.7%)	3 (0.6%)	0 (0%)	0 (0%)
Musculoskeletal pain	20 (4.1%)	2 (0.4%)	0 (0%)	0 (0%)	45 (9.2%)	1 (0.2%)	0 (0%)	0 (0%)
Myalgia	20 (4.1%)	0 (0%)	0 (0%)	0 (0%)	67 (13.7%)	3 (0.6%)	0 (0%)	0 (0%)
Bone pain	19 (3.9%)	1 (0.2%)	0 (0%)	0 (0%)	33 (6.7%)	2 (0.4%)	0 (0%)	0 (0%)
Dermatitis	16 (3.3%)	4 (0.8%)	0 (0%)	0 (0%)	2 (0.4%)	0 (0%)	0 (0%)	0 (0%)
Nail infection	14 (2.9%)	0 (0%)	1 (0.2%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)
Pain	14 (2.9%)	2 (0.4%)	0 (0%)	0 (0%)	30 (6.1%)	5 (1.0%)	0 (0%)	0 (0%)
Leukopenia	13 (2.7%)	3 (0.6%)	1 (0.2%)	0 (0%)	19 (3.9%)	4 (0.8%)	1 (0.2%)	0 (0%)
Thrombocytopaenia	12 (2.5%)	0 (0%)	2 (0.4%)	0 (0%)	80 (16.3%)	56 (11.4%)	14 (2.9%)	0 (0%)
Decreased haemoglobin	10 (2.0%)	1 (0.2%)	0 (0%)	0 (0%)	10 (2.0%)	4 (0.8%)	1 (0.2%)	0 (0%)
Hypoaesthesia	10 (2.0%)	1 (0.2%)	0 (0%)	0 (0%)	15 (3.1%)	0 (0%)	0 (0%)	0 (0%)
Muscular weakness	10 (2.0%)	1 (0.2%)	0 (0%)	0 (0%)	8 (1.6%)	0 (0%)	1 (0.2%)	0 (0%)
Decreased ejection fraction	9 (1.8%)	2 (0.4%)	0 (0%)	0 (0%)	5 (1.0%)	0 (0%)	0 (0%)	0 (0%)
Hypertension	9 (1.8%)	2 (0.4%)	0 (0%)	0 (0%)	22 (4.5%)	7 (1.4%)	0 (0%)	0 (0%)
Skin exfoliation	9 (1.8%)	1 (0.2%)	1 (0.2%)	0 (0%)	3 (0.6%)	0 (0%)	0 (0%)	0 (0%)

Cellulitis	8 (1.6%)	3 (0.6%)	1 (0.2%)	0 (0%)	6 (1.2%)	3 (0.6%)	0 (0%)	0 (0%)
Decreased neutrophil count	8 (1.6%)	1 (0.2%)	0 (0%)	0 (0%)	6 (1.2%)	0 (0%)	0 (0%)	0 (0%)
Lethargy	8 (1.6%)	0 (0%)	0 (0%)	0 (0%)	14 (2.9%)	2 (0.4%)	0 (0%)	0 (0%)
Lymphoedema	8 (1.6%)	1 (0.2%)	0 (0%)	0 (0%)	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)
Vertigo	8 (1.6%)	2 (0.4%)	0 (0%)	0 (0%)	9 (1.8%)	0 (0%)	0 (0%)	0 (0%)
Neck pain	7 (1.4%)	3 (0.6%)	0 (0%)	0 (0%)	21 (4.3%)	1 (0.2%)	0 (0%)	0 (0%)
Oral herpes	7 (1.4%)	1 (0.2%)	0 (0%)	0 (0%)	5 (1.0%)	0 (0%)	0 (0%)	0 (0%)
Gastritis	6 (1.2%)	0 (0%)	0 (0%)	0 (0%)	6 (1.2%)	1 (0.2%)	0 (0%)	0 (0%)
Gastroenteritis	6 (1.2%)	1 (0.2%)	0 (0%)	0 (0%)	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)
Hyperglycaemia	6 (1.2%)	1 (0.2%)	0 (0%)	0 (0%)	8 (1.6%)	3 (0.6%)	0 (0%)	0 (0%)
Hyponatraemia	6 (1.2%)	1 (0.2%)	1 (0.2%)	0 (0%)	2 (0.4%)	1 (0.2%)	3 (0.6%)	0 (0%)
Left ventricular dysfunction	6 (1.2%)	0 (0%)	0 (0%)	0 (0%)	5 (1.0%)	1 (0.2%)	0 (0%)	0 (0%)
Tachycardia	6 (1.2%)	0 (0%)	0 (0%)	0 (0%)	7 (1.4%)	1 (0.2%)	0 (0%)	0 (0%)
Decreased white blood cell count	5 (1.0%)	2 (0.4%)	0 (0%)	0 (0%)	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)
Herpes zoster	5 (1.0%)	1 (0.2%)	0 (0%)	0 (0%)	9 (1.8%)	1 (0.2%)	0 (0%)	0 (0%)
Infection	5 (1.0%)	1 (0.2%)	0 (0%)	0 (0%)	9 (1.8%)	0 (0%)	0 (0%)	0 (0%)
Pleural effusion	5 (1.0%)	0 (0%)	0 (0%)	0 (0%)	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)

Pneumonia	5 (1.0%)	1 (0.2%)	0 (0%)	0 (0%)	9 (1.8%)	3 (0.6%)	1 (0.2%)	1 (0.2%)
Pulmonary embolism	5 (1.0%)	3 (0.6%)	6 (1.2%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)
Vaginal infection	5 (1.0%)	1 (0.2%)	0 (0%)	0 (0%)	7 (1.4%)	0 (0%)	0 (0%)	0 (0%)
Bronchitis	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)	12 (2.4%)	1 (0.2%)	0 (0%)	0 (0%)
Confused state	4 (0.8%)	2 (0.4%)	0 (0%)	0 (0%)	8 (1.6%)	0 (0%)	1 (0.2%)	0 (0%)
Dysphagia	4 (0.8%)	1 (0.2%)	0 (0%)	0 (0%)	5 (1.0%)	0 (0%)	0 (0%)	0 (0%)
Erysipelas	4 (0.8%)	1 (0.2%)	0 (0%)	0 (0%)	2 (0.4%)	1 (0.2%)	0 (0%)	0 (0%)
Hypotension	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)	5 (1.0%)	0 (0%)	1 (0.2%)	0 (0%)
Increased transaminases	4 (0.8%)	1 (0.2%)	0 (0%)	0 (0%)	12 (2.4%)	3 (0.6%)	1 (0.2%)	0 (0%)
Rectal haemorrhage	4 (0.8%)	1 (0.2%)	0 (0%)	0 (0%)	9 (1.8%)	0 (0%)	0 (0%)	0 (0%)
Abnormal liver function test	3 (0.6%)	0 (0%)	0 (0%)	0 (0%)	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)
Ataxia	3 (0.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	1 (0.2%)	0 (0%)	0 (0%)
Cataract	3 (0.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Decreased platelet count	3 (0.6%)	0 (0%)	0 (0%)	0 (0%)	10 (2.0%)	4 (0.8%)	1 (0.2%)	0 (0%)
Hypoalbuminaemia	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)	4 (0.8%)	0 (0%)	0 (0%)	0 (0%)
Hypophosphataemia	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)
Jaundice	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Lymphopenia	3 (0-6%)	2 (0-4%)	0 (0%)	0 (0%)	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)
Menorrhagia	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)
Oesophagitis	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)
Proctalgia	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Tremor	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)	5 (1-0%)	1 (0-2%)	0 (0%)	0 (0%)
Decreased blood calcium	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Deep vein thrombosis	2 (0-4%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Generalised pruritus	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)
Haemorrhage	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Hepatocellular injury	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)
Malaise	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	3 (0-6%)	2 (0-4%)	0 (0%)	0 (0%)
Metrorrhagia	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	3 (0-6%)	2 (0-4%)	0 (0%)	0 (0%)
Pericardial effusion	2 (0-4%)	0 (0%)	1 (0-2%)	0 (0%)	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)
Peripheral motor neuropathy	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	3 (0-6%)	2 (0-4%)	0 (0%)	0 (0%)
Pleuritic pain	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Procedural pain	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	4 (0-8%)	1 (0-2%)	0 (0%)	0 (0%)
Skin toxicity	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Syncope	2 (0-4%)	4 (0-8%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Tooth abscess	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Urticaria	2 (0-4%)	5 (1-0%)	0 (0%)	0 (0%)	5 (1-0%)	0 (0%)	0 (0%)	0 (0%)
<i>C. difficile</i> colitis	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Colitis	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Contact dermatitis	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	5 (1-0%)	1 (0-2%)	0 (0%)	0 (0%)
Decreased blood phosphorus	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Decreased blood potassium	1 (0-2%)	3 (0-6%)	0 (0%)	0 (0%)	5 (1-0%)	2 (0-4%)	0 (0%)	0 (0%)
Decreased lymphocyte count	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Device-related infection	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)	4 (0-8%)	0 (0%)	0 (0%)	0 (0%)
Epilepsy	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Exfoliative rash	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)
Fall	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	11 (2-2%)	0 (0%)	0 (0%)	0 (0%)
Femur fracture	1 (0-2%)	2 (0-4%)	0 (0%)	0 (0%)	1 (0-2%)	2 (0-4%)	0 (0%)	0 (0%)
Food poisoning	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)
Gastrointestinal pain	1 (0-2%)	2 (0-4%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Hypercalcaemia	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)	5 (1-0%)	0 (0%)	0 (0%)	0 (0%)

Ileus	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Increased hepatic enzymes	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Increased international normalised ratio	1 (0-2%)	2 (0-4%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Neuralgia	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	3 (0-6%)	1 (0-2%)	0 (0%)	0 (0%)
Neurotoxicity	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	6 (1-2%)	0 (0%)	0 (0%)	0 (0%)
Pain of skin	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Plantar erythema	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Proctitis	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Renal failure	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)
Upper respiratory tract viral infection	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)
Venous thrombosis	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Abnormal AST	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Abnormal hepatic function	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Acute haemorrhagic conjunctivitis	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Acute myeloid leukaemia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)
Acute respiratory distress syndrome	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)
Affect liability	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)

Agitation	0 (0%)	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Anaemia of malignant disease	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Angina pectoris	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Appendicitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Areflexia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Atrial fibrillation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Bacteraemia	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Bacterial pneumonia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Cartilage injury	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Catheter site infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)
Cerebral ischaemia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)
Cerebrovascular accident	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Cholangitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Cholesteatoma	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Coma	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Coronary artery disease	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Costochondritis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)

Decreased blood sodium	0 (0%)	2 (0-4%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)
Decreased performance status	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)
Failure to thrive	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Febrile neutropenia	0 (0%)	2 (0-4%)	3 (0-6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Femoral neck fracture	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Fibular fracture	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)
Gastric infection	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Gastric ulcer	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)
Gastrointestinal haemorrhage	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)
Genital erosion	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
H1N1 influenza	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hemiplegia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Hepatotoxicity	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Hip fracture	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Hydrocephalus	0 (0%)	1 (0-2%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Increased GGT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (0-8%)	5 (1-0%)	1 (0-2%)	0 (0%)
Increased lipase	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)

Infected neoplasm	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Intestinal haemorrhage	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Intestinal obstruction	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Intracardiac thrombosis	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Labile blood pressure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Ligament rupture	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Listeriosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)
Metabolic encephalopathy	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)
Multi-organ failure	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Neutropenic sepsis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)
Osteonecrosis of the jaw	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (0-8%)	1 (0-2%)	0 (0%)	0 (0%)
Parotitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Pathological fracture	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)
Peptic ulcer haemorrhage	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Pericarditis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Petechiae	0 (0%)	0 (0%)	0 (0%)	0 (0%)	11 (2-2%)	1 (0-2%)	0 (0%)	0 (0%)
Pharyngitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	8 (1-6%)	1 (0-2%)	0 (0%)	0 (0%)

Photophobia	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	2 (0-4%)	0 (0%)	0 (0%)	0 (0%)
Portal hypertension	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (0-4%)	1 (0-2%)	0 (0%)	0 (0%)
Postoperative anaemia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Pregnancy	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Prolonged prothrombin time	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Pulmonary oedema	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Renal cell carcinoma	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Renal impairment	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Respiratory failure	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Sepsis	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	1 (0-2%)	1 (0-2%)	0 (0%)	0 (0%)
Spinal column stenosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Staphylococcal infection	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Status epilepticus	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)
Stress urinary incontinence	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)
Subdural haemorrhage	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Subileus	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Substance-induced psychotic disorder	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0-2%)	0 (0%)	0 (0%)

Thrombosis	0 (0%)	2 (0.4%)	0 (0%)	0 (0%)	1 (0.2%)	1 (0.2%)	0 (0%)	0 (0%)
Thrombosis in device	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (0.6%)	1 (0.2%)	0 (0%)	0 (0%)
Tooth infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (0.8%)	1 (0.2%)	0 (0%)	0 (0%)
Toxic hepatitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Transient ischaemic attack	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Upper gastrointestinal haemorrhage	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Ureteric obstruction	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Urinary tract obstruction	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Urosepsis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Uterine cancer	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Uterine haemorrhage	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)
Venous embolism	0 (0%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Vocal cord paralysis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	1 (0.2%)	0 (0%)	0 (0%)
Wrist fracture	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)

Table S3: Summary of safety events in patients who crossed over from Capecitabine plus lapatinib to trastuzumab emtansine

	Trastuzumab emtansine (n=136)	
	All grades	Grade 3 or 4
Epistaxis	36 (26.5%)	0 (0%)
Nausea	35 (25.7%)	0 (0%)
Fatigue	30 (22.1%)	2 (1.5%)
Headache	28 (20.6%)	1 (0.7%)
Increased AST	25 (18.4%)	2 (1.5%)
Asthenia	24 (17.6%)	4 (2.9%)
Thrombocytopenia	23 (16.9%)	6 (4.4%)
Constipation	22 (16.2%)	0 (0%)
Arthralgia	21 (15.4%)	0 (0%)
Decreased appetite	21 (15.4%)	2 (1.5%)
Diarrhoea	20 (14.7%)	1 (0.7%)
Dry mouth	20 (14.7%)	0 (0%)
Pyrexia	20 (14.7%)	0 (0%)
Cough	18 (13.2%)	0 (0%)
Dyspnoea	17 (12.5%)	0 (0%)
Rash	17 (12.5%)	1 (0.7%)
Myalgia	16 (11.8%)	0 (0%)
Peripheral neuropathy	16 (11.8%)	0 (0%)
Increased ALT	14 (10.3%)	0 (0%)
Insomnia	14 (10.3%)	0 (0%)
Upper respiratory tract infection	14 (10.3%)	0 (0%)
Anaemia	11 (8.1%)	4 (2.9%)
Increased GGT	4 (2.9%)	3 (2.2%)

This table shows adverse events that occurred during crossover treatment with trastuzumab emtansine in patients who crossed over from treatment with capecitabine plus lapatinib to trastuzumab emtansine. All adverse events (grades 1–5) that occurred in at least 10% of patients and all grade 3–4 events that occurred in at least 2% of patients are listed. There were no grade 5 adverse events.